These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 705170)

  • 1. Treatment of gout with alternate-day hypo-uricaemic drugs.
    Nishizawa T; Nishida Y; Masuda T; Akaoka I
    Rheumatol Rehabil; 1978 Aug; 17(3):143-9. PubMed ID: 705170
    [No Abstract]   [Full Text] [Related]  

  • 2. [Therapy of hyperuricemia and gout. Effect of a combination therapy of allopurinol with benzbromarone].
    Matzkies F
    Fortschr Med; 1983 May; 101(20):953-9. PubMed ID: 6873850
    [No Abstract]   [Full Text] [Related]  

  • 3. [Treatment of hyperuricaemia with a combination of allopurinol and benzbromaron (author's transl)].
    Matzkies F; Berg G
    Dtsch Med Wochenschr; 1976 Oct; 101(43):1568-70. PubMed ID: 991731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Reducing the risks in the treatment of gout and hyperuricaemia (author's transl)].
    Mertz DP
    Dtsch Med Wochenschr; 1976 Aug; 101(35):1288-92. PubMed ID: 782809
    [No Abstract]   [Full Text] [Related]  

  • 5. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout.
    Reinders MK; Haagsma C; Jansen TL; van Roon EN; Delsing J; van de Laar MA; Brouwers JR
    Ann Rheum Dis; 2009 Jun; 68(6):892-7. PubMed ID: 18633127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Long lasting normalization of uric acid after combination therapy with 300 mg allopurinol and 60 mg benzbromarone in patients with gout and hyperuricemia].
    Matzkies F
    Med Klin (Munich); 1992 Sep; 87(9):460-2. PubMed ID: 1406482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Indications for and methods of allopurinol-benzbromarone combination therapy in the treatment of hyperuricemic metabolic disorders].
    Heidelmann G; Burck G; Dauterstedt W; Heinrich JJ; Ohlmer R
    Z Arztl Fortbild (Jena); 1982 Mar; 76(5):177-81. PubMed ID: 6896252
    [No Abstract]   [Full Text] [Related]  

  • 8. [Uric acid lowering effects of benzbromarone (Harolan) by increasing uric acid excretion].
    Fortschr Med; 1979 May; 97(17):835-6. PubMed ID: 437646
    [No Abstract]   [Full Text] [Related]  

  • 9. [Long-term therapy with benzbromarone in uric arthritis].
    Bröll H; Sochor H; Tausch G; Eberl R
    Wien Med Wochenschr; 1975 Sep; 125(28):546-8. PubMed ID: 816095
    [No Abstract]   [Full Text] [Related]  

  • 10. [Current therapy: combined drug therapy of hyperuricemia, gout and alcohol induced fatty liver].
    Mertz DP
    Fortschr Med; 1983 May; 101(18):851-3. PubMed ID: 6862346
    [No Abstract]   [Full Text] [Related]  

  • 11. [Allomaron in hyperuricemia and gout].
    Barsom S
    ZFA (Stuttgart); 1979 Aug; 55(24):1336-40. PubMed ID: 539082
    [No Abstract]   [Full Text] [Related]  

  • 12. [Isolated or combined drug therapy of hyperuricemia?].
    Mertz DP
    Dtsch Med Wochenschr; 1977 Jul; 102(30):1096-7. PubMed ID: 891391
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy of benzbromarone compared to allopurinol in lowering serum uric acid level in hyperuricemic patients.
    Hanvivadhanakul P; Akkasilpa S; Deesomchok U
    J Med Assoc Thai; 2002 Jun; 85 Suppl 1():S40-7. PubMed ID: 12188443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of combined low dose of Allopurinol and benzbromarone compared to standard dose of Allopurinol in hyperuricemia.
    Akkasilpa S; Osiri M; Deesomchok U; Avihingsanon Y
    J Med Assoc Thai; 2004 Sep; 87(9):1087-91. PubMed ID: 15516011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effectiveness and tolerance of long-term uricosuric treatment].
    Berg H
    Z Gesamte Inn Med; 1990 Dec; 45(23):719-20. PubMed ID: 2102029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hyperuricemia and gout--treatment].
    Gröbner W; Walter-Sack I
    Dtsch Med Wochenschr; 2002 Feb; 127(5):210-3. PubMed ID: 11821994
    [No Abstract]   [Full Text] [Related]  

  • 17. [The effect on uric acid and other laboratory parameters. A long-term study].
    Dorn M
    ZFA (Stuttgart); 1982 Feb; 58(5):296-300. PubMed ID: 7043937
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of the gout and other forms of crystal-induced arthritis.
    Rodnan GP
    Bull Rheum Dis; 1982; 32(5):43-53. PubMed ID: 6762236
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout.
    Perez-Ruiz F; Alonso-Ruiz A; Calabozo M; Herrero-Beites A; García-Erauskin G; Ruiz-Lucea E
    Ann Rheum Dis; 1998 Sep; 57(9):545-9. PubMed ID: 9849314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical findings and therapy of gout with special reference to the metabolic effects of sulfinpyrazone (Anturan) and allopurinol (Zyloric)].
    Günther R; Knapp E
    Wien Klin Wochenschr; 1969 Nov; 81(45):817-20. PubMed ID: 5362152
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.